Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15535380 | 0.86 | MRGPRX4 (0.47) | MRGPRX4ADORA1CA1CA2CA9 | |
| SCHEMBL29391989 | 0.86 | MRGPRX4 (0.47) | MRGPRX4ADORA1CA1CA2CA9 | |
| SCHEMBL15535465 | 0.86 | AR (0.42) | CA1CA2CA9AR | |
| SCHEMBL15535340 | 0.84 | BCL2 (0.41) | — | |
| SCHEMBL15535016 | 0.81 | KLKB1 (0.55) | MRGPRX4CA1CA2CA9ACMSD | |
| SCHEMBL15535563 | 0.81 | KDM4E (0.50) | — | |
| SCHEMBL15535458 | 0.78 | RXRA (0.43) | CA2 | |
| SCHEMBL15536612 | 0.77 | FFAR1 (0.45) | CA1CA2 | |
| SCHEMBL15535762 | 0.76 | MAOA (0.41) | ADORA1 | |
| SCHEMBL12923381 | 0.76 | MRGPRX4 (0.49) | MRGPRX4ADORA1FOLH1ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855426-B1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2017-01-04 | — | — | EP | claimed |
| US-20150218124-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2015-08-06 | — | — | US | claimed |
| EP-2855426-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | Orion Corporation (FI) | 2015-04-08 | — | — | EP | claimed |
| CN-104334525-A | Catechol o-methyltransferase activity inhibiting compounds | ORION CORP | 2015-02-04 | — | — | CN | claimed |
| WO-2013175053-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2013-11-28 | — | — | WO | claimed |
| US-20220047540-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2022-02-17 | — | — | US | disclosed |
| US-20200352898-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2020-11-12 | — | — | US | disclosed |
| US-20190029990-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2019-01-31 | — | — | US | disclosed |
| US-20170165219-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2017-06-15 | — | — | US | disclosed |
| CN-104334525-B | catechol O-methyltransferase activity inhibiting compounds | 奥赖恩公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-2855426-B1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2017-01-04 | — | — | EP | disclosed |
| US-9458128-B2 | Catechol O-methyltransferase activity inhibiting compounds | ORION CORPORATION (FI) | 2016-10-04 | — | — | US | disclosed |
| US-20150218124-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2015-08-06 | — | — | US | disclosed |
| EP-2855426-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | Orion Corporation (FI) | 2015-04-08 | — | — | EP | disclosed |
| CN-104334525-A | Catechol o-methyltransferase activity inhibiting compounds | ORION CORP | 2015-02-04 | — | — | CN | disclosed |
| WO-2013175053-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165219-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | MRGPRX4 2603/4885ADORA1 1455/4885FOLH1 341/4885 |
| US-20200352898-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | MRGPRX4 2603/4885ADORA1 1455/4885FOLH1 341/4885 |
| US-20190029990-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | MRGPRX4 2603/4885ADORA1 1455/4885FOLH1 341/4885 |
| US-20150218124-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | MRGPRX4 2603/4885ADORA1 1455/4885FOLH1 341/4885 |
| US-20220047540-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | MRGPRX4 2603/4885ADORA1 1455/4885FOLH1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.